Medical Pharmacology Question Bank
Chapter: Chapter 13 — Opioid Analgesics — Module: Module 3 — Adverse Effects, Toxicology, and Opioid Antagonists
Tier: Tier 3 — Clinical Vignette
1. A 52-year-old man with chronic low back pain is maintained on methadone 80 mg/day for opioid use disorder. He develops a fungal nail infection and is prescribed fluconazole by his primary care physician, who is unaware of the methadone regimen. One week later, the patient reports palpitations and dizziness, and his ECG shows a QTc interval of 530 ms. Which of the following best explains the mechanism responsible for this patient's prolonged QTc?
ANSWER: B
Rationale:
This question asked you to identify the pharmacokinetic mechanism by which a drug interaction between fluconazole and methadone results in clinically dangerous QTc prolongation. Methadone prolongs the QTc interval through direct blockade of cardiac hERG (I\u2091\u1d63) potassium channels; this is a pharmacological property of the methadone molecule itself and is dose-dependent, meaning that higher methadone plasma concentrations produce greater QTc prolongation and greater risk of torsades de pointes. Fluconazole is a potent inhibitor of CYP3A4 (cytochrome P450 3A4), the primary enzyme responsible for methadone oxidative metabolism; when CYP3A4 is inhibited, methadone clearance is reduced, plasma concentrations rise, and hERG blockade intensifies, pushing the QTc toward dangerous prolongation as seen in this patient whose QTc reached 530 ms, well above the threshold of 500 ms that warrants serious reassessment of the methadone regimen. Option A: Fluconazole does have some direct hERG-blocking activity at supratherapeutic concentrations, but this is not the primary mechanism in clinical practice; the dominant interaction is pharmacokinetic rather than a direct additive pharmacodynamic effect at the channel itself. Option C: Neither methadone nor fluconazole causes clinically significant renal potassium wasting at therapeutic doses; hypokalemia is a separate QTc risk factor but is not the mechanism responsible for this interaction, and this distractor incorrectly attributes the interaction to an electrolyte effect that neither drug reliably produces. Option D: Fluconazole does not displace methadone from plasma protein binding in a clinically meaningful way; pharmacokinetic drug interactions via protein-binding displacement are generally transient and self-correcting as free drug redistributes and is cleared, and this is not the mechanism by which azole antifungals raise methadone concentrations. Option E: Methadone's QTc prolongation is entirely independent of mu-opioid receptor activation; it is mediated by a non-opioid receptor mechanism (hERG blockade), and fluconazole has no known effect on myocardial mu-receptor density; this option conflates the opioid receptor pharmacology of methadone with its separate cardiac ion channel pharmacology.
2. A 67-year-old woman with metastatic breast cancer is started on extended-release oxycodone 20 mg twice daily for bone pain. She has no prior history of constipation. Her oncologist wants to initiate appropriate prophylaxis for opioid-induced constipation. Which of the following is the most appropriate first-line bowel regimen to prescribe at the time of opioid initiation?
ANSWER: D
Rationale:
This question asked you to identify the correct first-line prophylactic bowel regimen for opioid-induced constipation (OIC), a condition that affects 40–95% of patients on chronic opioid therapy and does not substantially tolerize over time. Opioid-induced constipation should be anticipated and prophylactically treated at opioid initiation; waiting until constipation becomes symptomatic and severe is a common and avoidable clinical error. The correct first-line approach is a stimulant laxative, most commonly a senna-docusate combination, because stimulant laxatives directly enhance propulsive motility through the myenteric plexus, counteracting the key mechanism of OIC (decreased propulsive peristalsis and increased segmental contractions from enteric mu-opioid receptor activation). The senna-docusate combination is the most widely recommended and guideline-supported first-line prophylactic regimen at opioid initiation. Option A: Docusate sodium alone as a stool softener is explicitly inadequate for OIC because it does not stimulate propulsive motility; it softens stool by surfactant action but does not address the primary motility deficit caused by opioid-induced enteric mu-receptor activation, and multiple guidelines recommend against docusate monotherapy for OIC. Option B: Withholding laxative therapy until the patient reports symptomatic constipation is incorrect practice; OIC should be treated prophylactically at the time opioid therapy is initiated, not reactively after symptoms develop; reactive management produces unnecessary patient suffering and is inconsistent with current guidelines. Option C: Methylnaltrexone (Relistor) is a peripherally restricted mu-opioid receptor antagonist (PAMORA) approved for OIC refractory to conventional laxative therapy in palliative care and chronic non-cancer pain; it is not initiated as first-line prophylaxis at opioid start and is reserved for patients who have failed adequate stimulant laxative therapy. Option E: Lactulose and bisacodyl suppositories are not the standard first-line prophylactic regimen for OIC; lactulose is an osmotic laxative used as a second-line agent, and routine rectal suppository administration is not part of standard OIC prophylaxis guidelines; this combination lacks guideline support as an initial regimen.
3. A 31-year-old man with opioid use disorder has been using heroin daily and presents requesting naltrexone (Vivitrol) pharmacotherapy for relapse prevention. His last heroin use was 36 hours ago. He is motivated, denies current withdrawal symptoms beyond mild anxiety, and has completed a supervised medical detoxification. His urine toxicology is opioid-positive. What is the most important reason to delay naltrexone initiation at this visit?
ANSWER: A
Rationale:
This question asked you to identify the critical safety reason for delaying naltrexone initiation after recent opioid use. Naltrexone is a long-acting full opioid antagonist with very high mu-opioid receptor (MOR) affinity; when administered to a physically dependent patient who still has meaningful receptor occupancy by opioids, naltrexone abruptly displaces agonist molecules from receptors and produces antagonist-precipitated withdrawal, which is typically severe, abrupt in onset, and particularly distressing — qualitatively worse than naturally occurring withdrawal. For patients who have used short-acting opioids such as heroin, oxycodone, or hydrocodone, the standard recommendation is a minimum of 7–10 days of confirmed opioid abstinence before naltrexone initiation, with provocative testing using a small naloxone challenge dose prudent in ambiguous cases. This patient is only 36 hours out from his last heroin use with a positive urine toxicology and is at very high risk of precipitated withdrawal if naltrexone is given now. Option B: Naltrexone is metabolized primarily to its active metabolite 6-beta-naltrexol by dihydrodiol dehydrogenase and to a lesser extent by CYP enzymes; opioid metabolites in urine do not competitively inhibit naltrexone metabolism in any clinically meaningful way, and this option describes a pharmacokinetic mechanism that does not exist. Option C: Naltrexone does not bind circulating opioid metabolites in plasma to form toxic adducts; it is a competitive receptor antagonist that acts at opioid receptors in the CNS and peripheral tissues, not a plasma-binding agent, and hepatotoxicity is a recognized risk of naltrexone at high doses but is unrelated to plasma opioid metabolite levels. Option D: The 30-day washout described in this option is fabricated; the requirement is not a 30-day washout after any opioid exposure but rather confirmed physical detoxification (7–10 days for short-acting opioids, longer for methadone) before any formulation of naltrexone is initiated; the extended-release injection carries the same receptor-based precipitated withdrawal risk as oral naltrexone if given too soon. Option E: While naltrexone does modulate opioid-mediated dopamine release in reward circuits and this is relevant to its mechanism in alcohol use disorder, it does not simultaneously block dopamine receptors directly; the severe dysphoric reaction described in this option is not a recognized pharmacological consequence of initiating naltrexone in the presence of opioid metabolites — the actual risk is precipitated withdrawal, not dopamine receptor blockade.
4. Paramedics are called to a scene where a 28-year-old man is found unresponsive. On arrival they find him with a respiratory rate of 4 breaths/minute, pinpoint pupils bilaterally, and profound unresponsiveness to sternal rub. A syringe is found nearby. Which of the following best describes the clinical triad that is sufficient to initiate empirical naloxone therapy in this patient, without waiting for toxicological confirmation?
ANSWER: C
Rationale:
This question asked you to identify the clinical triad that defines the opioid toxidrome and is sufficient to initiate empirical naloxone therapy without waiting for toxicological confirmation. The opioid overdose syndrome is defined by three cardinal features: CNS depression (ranging from sedation to deep unresponsiveness), respiratory depression (hypoventilation, slow respiratory rate, or apnea), and miosis (pinpoint pupils from central mu-opioid receptor activation at the Edinger-Westphal nucleus). Recognition of this triad in a patient with altered level of consciousness, particularly in a clinical context suggesting possible opioid exposure, is sufficient to initiate naloxone immediately; toxicological confirmation is not required before treatment because the time from onset of respiratory depression to irreversible anoxic brain injury is typically 3–5 minutes without airway support. Option A: The cardiovascular effects of opioid overdose (mild bradycardia from vagotonia, possible hypotension in volume-depleted patients) are not part of the defining toxidrome triad and are not the primary diagnostic markers used for empirical naloxone initiation; hypotension and bradycardia are not sufficiently specific to opioids among causes of toxicological unresponsiveness, and this option mischaracterizes the cardinal triad. Option B: Serotonin syndrome presents with hyperthermia, agitation, clonus, and hyperreflexia — it does not typically present with profound unresponsiveness, pinpoint pupils, and respiratory depression, and it is not considered before naloxone in a patient with the opioid toxidrome triad; there is no contraindication to naloxone in serotonin syndrome, and delaying treatment to exclude it would be dangerous. Option D: Miosis (pinpoint pupils), not mydriasis (dilated pupils), is the characteristic pupillary finding in opioid overdose; mydriasis would suggest stimulant or anticholinergic toxidrome; diaphoresis is not a characteristic feature of opioid overdose at rest; this option contains factual errors that make it an incorrect characterization of the opioid toxidrome. Option E: Hypoglycemia produces altered consciousness but is not part of the opioid toxidrome; Kussmaul respirations are a feature of metabolic acidosis (e.g., diabetic ketoacidosis), not opioid overdose; while hypoglycemia should be checked and treated in any unresponsive patient, it does not need to be excluded before administering naloxone to a patient who presents with the triad of CNS depression, respiratory depression, and miosis.
5. A 27-year-old woman undergoes cesarean delivery under spinal anesthesia with intrathecal bupivacaine and morphine 150 mcg. In the recovery room, she develops intense pruritus of the face, nose, and neck. The nurse administers diphenhydramine 25 mg IV, but the pruritus persists and the patient rates it 8/10 in severity. Which of the following most accurately explains why antihistamine therapy is largely ineffective for this patient's pruritus, and what is a more mechanistically rational treatment?
ANSWER: E
Rationale:
This question asked you to identify why antihistamine therapy fails for neuraxial opioid-induced pruritus (OIP) and to apply knowledge of the correct mechanism to select a rational treatment. Neuraxial OIP — particularly the generalized and craniofacial pruritus that follows intrathecal opioid administration — is not primarily a histamine-mediated phenomenon; this is a critical clinical distinction with direct therapeutic consequences. The dominant mechanism is central mu-opioid receptor (MOR) activation in the dorsal horn of the spinal cord and in medullary itch-modulating circuits, including the medullary dorsal horn; rostral spread of morphine in the cerebrospinal fluid (CSF) to these brainstem centers explains the characteristic craniofacial distribution (nose, face, neck) seen in this patient after intrathecal morphine. Diphenhydramine's modest benefit in some patients derives from sedation rather than direct antipruritic action at the causative receptor. The most mechanistically rational treatments are low-dose opioid antagonists: naloxone at 0.25–1 mcg/kg/hr as a continuous IV infusion, or nalbuphine 2.5–5 mg IV, which preferentially disrupt the itch-signaling MOR population at doses that spare analgesia; ondansetron 4–8 mg IV is also effective through serotonergic modulation of dorsal horn itch signaling. Option A: There is no clinically meaningful intrathecal or spinal cord mast cell degranulation mechanism for OIP, and H2 antagonists such as ranitidine are not used and have no established role in OIP management; this option incorrectly attributes the mechanism to spinal histamine release and misidentifies the relevant receptor subtype. Option B: Neuraxial opioid pruritus is not mediated by kappa-opioid receptor (KOR) activation; in fact, KOR agonism (e.g., by nalbuphine, a KOR agonist and partial MOR antagonist) is an effective treatment for OIP because KOR activation in the spinal cord directly inhibits MOR-mediated itch signaling; this option inverts the kappa receptor's role in the pathophysiology of OIP. Option C: Neuraxial opioid pruritus following intrathecal administration is not caused by peripheral mast cell degranulation at the injection site; it is a centrally mediated phenomenon, and topical hydrocortisone has no established role in treating OIP regardless of route; this option confuses the mechanism with the local histamine-mediated reactions seen with rapid IV morphine administration. Option D: Diphenhydramine's failure in neuraxial OIP is a predictable pharmacological consequence of its mechanism of action (H1 receptor antagonism), not a consequence of atypical CYP2D6 metabolism; CYP2D6 genotyping is not indicated and would not change the management of OIP; this option incorrectly attributes a pharmacokinetic explanation to what is a pharmacodynamic mismatch.
6. A 74-year-old man with obesity and obstructive sleep apnea (OSA) undergoes elective colectomy under general anesthesia. At the end of the procedure, the anesthesiologist administers intrathecal morphine 300 mcg for postoperative analgesia. He is extubated and transferred to the surgical floor in stable condition. At 8 hours postoperatively, the floor nurse finds him somnolent with a respiratory rate of 6 breaths/minute and an SpO2 of 88% on room air. Which of the following best explains the mechanism and timing of this complication?
ANSWER: B
Rationale:
This question asked you to explain the mechanism and characteristic timing of delayed respiratory depression following intrathecal morphine, one of the most dangerous adverse effects of neuraxial opioid administration. Morphine is hydrophilic (low lipid solubility), which means it diffuses poorly into spinal cord tissue and lipid membranes and instead remains dissolved in the CSF in high concentration following intrathecal injection. This hydrophilicity drives slow rostral (upward) transport of morphine through the CSF over a period of hours; as morphine reaches the brainstem — specifically the pre-Botzinger complex (the medullary respiratory rhythm generator) and the nucleus tractus solitarius — it activates mu-opioid receptors in these respiratory control centers and produces progressive respiratory depression. The hallmark of this process is its delayed and potentially late onset, typically 6–12 hours after intrathecal injection and occasionally as late as 18 hours, in contrast to the early (30–90 minute) respiratory depression seen with lipophilic agents such as intrathecal fentanyl that distribute rapidly into spinal tissue and systemic circulation. This patient's risk is compounded by two major risk factors: obesity and obstructive sleep apnea, both of which increase susceptibility to opioid-induced respiratory depression. Option A: Intrathecal morphine is not absorbed into the epidural venous plexus as an IV bolus equivalent; while some systemic absorption does occur from the intrathecal space, this is not the mechanism of delayed respiratory depression and would not produce the characteristic 6–12 hour delayed onset; this option conflates intrathecal pharmacokinetics with systemic IV administration. Option C: P-glycoprotein is an efflux transporter that limits CNS entry of many drugs by pumping them back into the blood across the blood-brain barrier; it does not secrete morphine into the CSF in a clinically meaningful active transport mechanism; this option fabricates a transport pharmacology that does not underlie intrathecal morphine's clinical behavior. Option D: Delayed respiratory depression from intrathecal morphine is a supraspinal brainstem phenomenon mediated through rostral CSF transport to medullary respiratory centers, not a spinal cord mechanism involving phrenic nucleus GABA interneuron inhibition; while opioids do modulate spinal interneuron activity, the clinical syndrome of delayed respiratory depression is not caused by cervical spinal cord GABA circuitry. Option E: Glucuronidation of morphine to M6G occurs primarily in the liver via UGT2B7; the spinal cord does not contain significant glucuronidase activity capable of producing clinically relevant M6G concentrations from intrathecal morphine; the delayed respiratory depression is not due to M6G accumulation from intrathecal metabolism, which is a fabricated pharmacokinetic pathway.
7. A 58-year-old man with chronic lumbar radiculopathy has been taking scheduled oxycodone 10 mg three times daily for 18 months. He now reports that he requires higher doses to achieve the same degree of pain relief, and his nurse documents that he continues to require daily senna use to manage constipation. He denies compulsive drug-seeking, continued use despite harm, or loss of control over his opioid use. Which of the following statements most accurately characterizes the pharmacological phenomena present in this patient?
ANSWER: D
Rationale:
This question asked you to correctly distinguish among tolerance, physical dependence, and opioid use disorder (OUD) — three related but fundamentally distinct phenomena that are frequently conflated in clinical practice with serious consequences for patient care and documentation. Tolerance is defined as the reduction in pharmacological effect produced by a given dose of opioid following repeated exposure, requiring dose escalation to maintain the same effect; it develops at different rates for different opioid effects. Physical dependence is a neuroadaptive state in which the nervous system has adjusted its normal function to require the continued presence of the opioid; abrupt removal produces withdrawal. OUD, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), is a problematic pattern of opioid use characterized by loss of control, continued use despite harm, compulsive drug-seeking, and neurobiological changes in reward and executive control circuitry — features this patient explicitly does not exhibit. A critical point illustrated in this scenario is that tolerance to opioid effects develops at different rates across organ systems: tolerance to analgesia, sedation, and euphoria develops relatively rapidly, while tolerance to constipation and miosis develops minimally even with prolonged exposure; this is why this patient continues to require daily stimulant laxative therapy despite 18 months of opioid use. Option A: Dose escalation from analgesic tolerance in the context of a legitimate pain condition is not a DSM-5 criterion for OUD, and this patient explicitly lacks the defining behavioral features of OUD (loss of control, continued use despite harm, compulsive drug-seeking); conflating tolerance with OUD misrepresents the diagnosis and may result in inappropriate withholding of necessary pain therapy and stigmatizing documentation. Option B: Tolerance and addiction (OUD) are distinct phenomena with different neurobiological substrates; tolerance involves receptor-level pharmacological adaptation (desensitization, downregulation, reduced G-protein coupling efficiency), while OUD involves maladaptive plasticity in reward, motivation, and executive control circuitry; the claim that they are the same neurobiological process is pharmacologically incorrect. Option C: The persistent need for senna does not indicate that tolerance is complete or that all organ systems have adapted equally; it demonstrates the opposite — that GI tolerance develops minimally, meaning the clinician cannot assume that tolerance has also rendered the patient safe from respiratory depression at escalating doses; respiratory depression tolerance develops more slowly than analgesic tolerance, and dose escalation requires careful clinical monitoring. Option E: Receptor downregulation with prolonged opioid exposure does not eliminate physical dependence or make abrupt discontinuation safe; it is a contributor to tolerance but does not prevent withdrawal syndrome upon abrupt discontinuation; opioid tapering at 10–20% of total daily dose every 1–2 weeks is the standard approach to managing discontinuation in physically dependent patients.
8. A 71-year-old man with advanced pancreatic cancer is receiving sustained-release morphine 60 mg twice daily for pain management in a palliative care setting. Despite scheduled senna-docusate twice daily and as-needed polyethylene glycol, he has not had a bowel movement in 6 days and reports significant abdominal discomfort. His pain is reasonably well controlled and he has not requested breakthrough analgesia. Which of the following agents would be most appropriate to add, and what is the pharmacological basis for its ability to relieve constipation without reversing analgesia or causing withdrawal?
ANSWER: A
Rationale:
This question asked you to select the appropriate peripherally restricted mu-opioid receptor antagonist (PAMORA) for opioid-induced constipation (OIC) refractory to conventional laxative therapy in a palliative care patient, and to explain the pharmacological basis for its selective peripheral action. Methylnaltrexone (Relistor) is a quaternary ammonium derivative of naltrexone; the quaternary ammonium group confers a permanent positive charge that dramatically reduces lipid solubility and prevents clinically meaningful blood-brain barrier penetration at therapeutic doses. This peripheral restriction allows methylnaltrexone to selectively antagonize mu-opioid receptors (MOR) in the enteric nervous system — reversing the coordinated GI motility changes responsible for OIC (decreased peristalsis, increased segmental contractions, increased sphincter tone) — without displacing morphine from central MOR and without triggering systemic opioid withdrawal. Subcutaneous methylnaltrexone is approved specifically for OIC in patients with advanced illness in palliative care when conventional laxative therapy has been inadequate, precisely the clinical scenario presented here, with typical onset of laxation within 30–60 minutes in responsive patients. Option B: Oral naloxone at full antagonist doses (50 mg) would reverse central analgesia; while oral naloxone does have low oral bioavailability (approximately 2–3%), full antagonist doses at 50 mg produce sufficient systemic absorption to reverse opioid analgesia and precipitate withdrawal in a dependent patient; low-dose oral naloxone is used in some fixed-dose combination products, but this option describes inappropriate full-dose systemic naloxone. Option C: Buprenorphine is a partial MOR agonist and kappa antagonist used for pain and opioid use disorder; adding buprenorphine to full agonist morphine therapy is pharmacologically complex — buprenorphine's high MOR affinity can competitively displace morphine and actually precipitate withdrawal in a morphine-dependent patient; it is not used to manage OIC and does not selectively restore enteric motility. Option D: Methadone does not have lower affinity for enteric MOR than morphine; all full mu-opioid agonists that reach the enteric nervous system produce OIC through the same peripheral MOR mechanism, and methadone rotation does not reliably reduce constipation; methadone has additional risks in this population including QTc prolongation and difficult equianalgesic dosing conversion. Option E: Neostigmine can increase intestinal propulsion through acetylcholinesterase inhibition and is used in specific contexts such as acute colonic pseudo-obstruction (Ogilvie syndrome), but it is not a standard treatment for OIC and is not a pharmacological solution that targets the opioid receptor mechanism; its use requires cardiac monitoring and clinical expertise not typically applied in palliative OIC management.
9. A 62-year-old woman with chronic pain is found unresponsive at home by her husband. EMS arrives to find her minimally responsive with a respiratory rate of 5 breaths/minute and pinpoint pupils. A fentanyl patch is visible on her upper arm. She is given naloxone 0.4 mg IV with excellent initial response — she wakes, is conversational, and her respiratory rate returns to 14 breaths/minute. She is transported to the emergency department. Forty minutes after naloxone administration, she becomes increasingly sedated again and her respiratory rate falls to 7 breaths/minute. Which of the following best explains this clinical course?
ANSWER: C
Rationale:
This question asked you to explain the mechanism of resedation (also called re-narcotization) following initial successful reversal of opioid overdose with naloxone — a critical clinical safety concept for managing overdoses involving long-acting opioids. Naloxone's elimination half-life is approximately 60–90 minutes, which is substantially shorter than virtually all clinically significant opioids; transdermal fentanyl, extended-release oxycodone, and methadone all have durations of action that far exceed naloxone's. When a single bolus dose of naloxone is administered and its plasma concentration falls through elimination, opioid agonist molecules that remained in the systemic circulation re-occupy the opioid receptors whose antagonist has been cleared, reinstating CNS and respiratory depression. This is the mechanistic basis for the mandatory monitoring period following naloxone administration and for the use of repeat naloxone boluses or a continuous naloxone infusion in hospital settings when overdose involves a long-acting opioid. For transdermal fentanyl specifically, the depot in the skin continues to release drug for hours even if the patch is removed, making repeat or continuous naloxone essential rather than a single-dose rescue. Option A: Paradoxical receptor sensitization producing rebound opioid hypersensitivity after naloxone administration is not a clinically recognized phenomenon; while opioid receptor upregulation can occur with chronic opioid use, an acute rebound sensitization within 40 minutes that makes the patient more susceptible to residual fentanyl is not a mechanism that explains resedation. Option B: This option contains a partially plausible premise (ongoing fentanyl release from the patch) but inverts the pharmacological mechanism; naloxone is a competitive antagonist that occupies receptors, and as it is eliminated, receptors become available for fentanyl to re-occupy; fentanyl does not physically displace naloxone from receptor binding sites — the competition is resolved by the concentration ratios of each agent at the receptor, which shift as naloxone is cleared. Option D: Naloxone does not have a pro-sedative metabolite; its primary metabolic product in humans is naloxone-3-glucuronide, which is pharmacologically inactive; no active pro-sedative metabolite of naloxone exists, and this option describes a fabricated pharmacological mechanism. Option E: While naloxone can precipitate withdrawal in opioid-dependent patients, the clinical presentation of withdrawal is characterized by autonomic hyperactivity (agitation, tachycardia, hypertension, diaphoresis), not sedation; the scenario describes a return of sedation and respiratory depression — the classical presentation of resedation — not withdrawal, and reduced cerebral perfusion sufficient to cause neurological depression from autonomic activation is not a recognized consequence of precipitated withdrawal.
10. A 44-year-old man is enrolled in a methadone maintenance treatment program for opioid use disorder. His current dose is 110 mg/day, which has been stable for 8 months. His baseline ECG obtained before methadone initiation showed a QTc of 420 ms. A routine 12-lead ECG obtained today shows a QTc of 480 ms. He is asymptomatic and denies palpitations or presyncope. His serum potassium is 3.8 mEq/L and magnesium is 1.9 mg/dL. He takes no other QTc-prolonging medications. Which of the following best describes the appropriate clinical response to a QTc of 480 ms in this patient?
ANSWER: E
Rationale:
This question asked you to apply published clinical guidance on QTc monitoring and threshold management in methadone-maintained patients. Methadone's dose-dependent QTc prolongation through hERG potassium channel blockade is a well-characterized and clinically important pharmacological property; guidelines from the American Pain Society and the American Heart Association provide specific QTc thresholds to guide clinical decision-making. The threshold framework is: QTc intervals below 450 ms require routine monitoring; intervals of 450–500 ms, as in this patient at 480 ms, warrant close monitoring with electrolyte optimization (ensure adequate potassium and magnesium), avoidance of any additional QTc-prolonging agents, re-evaluation of the clinical risk-benefit balance of continued methadone therapy, and more frequent ECG follow-up; a QTc exceeding 500 ms represents a serious threshold that warrants reassessment of the methadone regimen, including possible dose reduction, agent switch, or discontinuation depending on the full clinical picture. This patient is asymptomatic with normal electrolytes and no other QTc-prolonging agents, placing him in the monitoring-and-optimization category rather than the immediate intervention category. Option A: A QTc of 480 ms does not constitute an absolute contraindication requiring immediate methadone discontinuation; abrupt methadone discontinuation in an opioid use disorder patient carries its own serious clinical risks including precipitated withdrawal and relapse; the threshold for serious reassessment in published guidelines is 500 ms, not any elevation above baseline. Option B: A QTc of 480 ms is not within normal range and does not require only annual monitoring; it falls in the 450–500 ms range that requires closer surveillance and clinical action; the claim that guidelines only mandate action at QTc greater than 600 ms is factually incorrect and represents a dangerous underestimate of the monitoring thresholds. Option C: Immediate hospital admission and IV magnesium infusion are not indicated for an asymptomatic patient with a QTc of 480 ms and normal electrolytes; torsades de pointes risk is not imminent at 480 ms in an otherwise stable patient; this option describes an overly aggressive response that is not consistent with published methadone monitoring guidelines. Option D: Published guidelines do not mandate a 50% immediate dose reduction at any QTc exceeding 450 ms; dose reduction is considered for QTc intervals above 500 ms or for symptomatic patients, and dose changes in methadone maintenance require careful clinical judgment given the risk of destabilizing opioid use disorder treatment; this option overstates the required clinical response at the 450–500 ms threshold.
11. An anesthesiologist is planning neuraxial analgesia for a patient undergoing major abdominal surgery and must choose between intrathecal morphine and intrathecal fentanyl for postoperative pain control. The patient has no history of opioid use and no prior neuraxial opioid exposure. Which of the following most accurately describes a clinically important pharmacokinetic difference between intrathecal morphine and intrathecal fentanyl that affects both the analgesic duration and the adverse effect profile?
ANSWER: B
Rationale:
This question asked you to apply knowledge of the pharmacokinetic basis for the clinical differences between intrathecal morphine and intrathecal fentanyl. The key pharmacokinetic variable is lipid solubility. Morphine is hydrophilic (low lipid solubility, logP approximately 0.9), which means it distributes poorly into the lipid-rich spinal cord tissue and remains dissolved in the CSF in high concentration after intrathecal injection. This hydrophilicity drives several clinical consequences: prolonged analgesic duration (12–24 hours or more) due to sustained high CSF morphine concentrations at dorsal horn MOR; extensive rostral spread through the CSF over hours, reaching medullary itch circuits (producing the characteristic craniofacial pruritus) and medullary respiratory centers (producing delayed respiratory depression with onset typically 6–12 hours post-injection); and a substantially higher incidence of pruritus and delayed respiratory depression compared with intrathecal fentanyl. Fentanyl is lipophilic (logP approximately 3.9), distributing rapidly into spinal cord tissue and systemic circulation after intrathecal injection; its analgesic duration is shorter (2–4 hours), its respiratory depression occurs early (within 30–90 minutes) rather than late, and its pruritus incidence is lower because it does not undergo the extensive rostral CSF spread that characterizes hydrophilic agents. Option A: Intrathecal fentanyl does not have a longer analgesic duration than intrathecal morphine; fentanyl's high lipophilicity causes rapid redistribution out of the CSF into spinal cord tissue and systemic circulation, shortening its analgesic duration to 2–4 hours compared with morphine's 12–24+ hours; plasma protein binding is not the relevant variable governing intrathecal drug behavior — it is the lipid-water partition coefficient. Option C: Intrathecal morphine and fentanyl do not produce identical adverse effect profiles; the pharmacokinetic differences between them are clinically consequential and produce meaningfully different onset times, durations of analgesia, pruritus incidence, and respiratory depression timing; the claim that pharmacokinetics are irrelevant once drugs are intrathecally injected is incorrect. Option D: This option inverts the pharmacological relationship between lipophilicity and pruritus incidence; intrathecal morphine, not fentanyl, produces a higher incidence of pruritus because hydrophilic morphine remains in the CSF and undergoes rostral spread to medullary itch centers; lipophilic fentanyl distributes locally into spinal cord tissue and does not spread rostrally in the CSF to the same extent. Option E: Intrathecal morphine's hydrophilicity actually slows its absorption across the spinal cord vasculature into the systemic circulation rather than accelerating it; this slow systemic absorption is precisely why intrathecal morphine produces delayed (6–12 hour) rather than early respiratory depression; this option inverts the pharmacokinetic behavior of hydrophilic agents and incorrectly describes the timing and mechanism of intrathecal morphine's respiratory effects.